<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1615">
  <stage>Registered</stage>
  <submitdate>3/07/2007</submitdate>
  <approvaldate>3/07/2007</approvaldate>
  <nctid>NCT00496938</nctid>
  <trial_identification>
    <studytitle>XIENCE V: SPIRIT WOMEN</studytitle>
    <scientifictitle>A Clinical Evaluation of the XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Women With de Novo Coronary Artery Lesions</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>07-377</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Coronary Artery Stenosis</healthcondition>
    <healthcondition>Coronary Arteriosclerosis</healthcondition>
    <healthcondition>Coronary Artery Disease</healthcondition>
    <healthcondition>Coronary Artery Restenosis</healthcondition>
    <healthcondition>Total Coronary Occlusion</healthcondition>
    <healthcondition>Stent Thrombosis</healthcondition>
    <healthcondition>Vascular Disease</healthcondition>
    <healthcondition>Myocardial Ischemia</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Clotting disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - XIENCE V®/ XIENCE PRIME

Other: 1 - Observational cohort using an all-comers design


Treatment: devices: XIENCE V®/ XIENCE PRIME
Coronary artery placement of a XIENCE V®/ XIENCE PRIME Everolimus Eluting Stent System

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Adjudicated Composite rate of all Death, all Myocardial Infarction (MI) and Target Vessel Revascularization (TVR)</outcome>
      <timepoint>at 1 year</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Acute Success (Clinical Device Success and Clinical Procedure Success)</outcome>
      <timepoint>Acute</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adjudicated Stent Thrombosis (Definite, Probable, Possible)</outcome>
      <timepoint>at 30 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adjudicated revascularization (TLR/TVR/all revascularizations)</outcome>
      <timepoint>at 30 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adjudicated Composite rate of Cardiac Death, MI attributed to the target vessel and CI-TLR.</outcome>
      <timepoint>at 30 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adjudicated Composite rate of all Death, all MI and Target Vessel Revascularization (TVR).</outcome>
      <timepoint>at 30 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adjudicated Composite rate of all Death, all MI and all Revascularization (TLR/TVR/non TVR.</outcome>
      <timepoint>at 30 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adjudicated Cardiac Death, Non-Cardiovascular Death, Vascular Death, Q-wave MI and Non Q-wave MI (Peri-Procedural, Unrelated to PCI).</outcome>
      <timepoint>at 30 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adjudicated Stent Thrombosis (Definite, Probable, Possible)</outcome>
      <timepoint>at 240 Days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adjudicated Stent Thrombosis (Definite, Probable, Possible)</outcome>
      <timepoint>at 1 Year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adjudicated Stent Thrombosis (Definite, Probable, Possible)</outcome>
      <timepoint>at 2 Years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adjudicated revascularization (TLR/TVR/all revascularizations)</outcome>
      <timepoint>at 240 Days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adjudicated revascularization (TLR/TVR/all revascularizations)</outcome>
      <timepoint>at 1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adjudicated revascularization (TLR/TVR/all revascularizations)</outcome>
      <timepoint>at 2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adjudicated Composite rate of Cardiac Death, MI attributed to the target vessel and CI-TLR.</outcome>
      <timepoint>at 240 Days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adjudicated Composite rate of Cardiac Death, MI attributed to the target vessel and CI-TLR.</outcome>
      <timepoint>at 1 Year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adjudicated Composite rate of Cardiac Death, MI attributed to the target vessel and CI-TLR.</outcome>
      <timepoint>at 2 Years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adjudicated Composite rate of all Death, all MI and Target Vessel Revascularization (TVR).</outcome>
      <timepoint>at 240 Days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adjudicated Composite rate of all Death, all MI and Target Vessel Revascularization (TVR).</outcome>
      <timepoint>at 1 Year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adjudicated Composite rate of all Death, all MI and Target Vessel Revascularization (TVR).</outcome>
      <timepoint>at 2 Years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adjudicated Composite rate of all Death, all MI and all Revascularization (TLR/TVR/non TVR.</outcome>
      <timepoint>at 240 Days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adjudicated Composite rate of all Death, all MI and all Revascularization (TLR/TVR/non TVR.</outcome>
      <timepoint>at 1 Year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adjudicated Composite rate of all Death, all MI and all Revascularization (TLR/TVR/non TVR.</outcome>
      <timepoint>at 2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adjudicated Cardiac Death, Non-Cardiovascular Death, Vascular Death, Q-wave MI and Non Q-wave MI (Peri-Procedural, Unrelated to PCI).</outcome>
      <timepoint>at 240 Days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adjudicated Cardiac Death, Non-Cardiovascular Death, Vascular Death, Q-wave MI and Non Q-wave MI (Peri-Procedural, Unrelated to PCI).</outcome>
      <timepoint>at 1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adjudicated Cardiac Death, Non-Cardiovascular Death, Vascular Death, Q-wave MI and Non Q-wave MI (Peri-Procedural, Unrelated to PCI).</outcome>
      <timepoint>at 2 Years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>General 

          -  Patient must be female.

          -  Patient must be at least 18 years of age.

          -  Patient is able to verbally confirm understanding of risks, benefits and treatment
             alternatives and she or her legally authorized representative provides written
             informed consent prior to any study related procedure, as approved by the appropriate
             Medical Ethics Committee of the respective clinical site.

          -  Patient must have evidence of myocardial ischemia (e.g., stable or unstable angina,
             silent ischemia, positive functional study or a reversible change in the
             electrocardiogram (ECG) consistent with ischemia).

          -  Patient must be an acceptable candidate for coronary artery bypass graft (CABG)
             surgery.

          -  Patient must agree to undergo all CIP-required follow-up examinations.

          -  Patients of childbearing potential must have had a negative pregnancy test within 7
             days before treatment, and must not be nursing at the time of treatment.

        Angiographic 

          -  Patients' artery morphology and disease is suitable to be optimally treated with a
             maximum of 4 planned study stents.

          -  Target lesions must be de novo lesions (no prior stent implant, no prior
             brachytherapy).

          -  Target vessel reference diameter must be between 2.5 mm and 4.0 mm by visual estimate.
             The diameter range will be expanded to 2.25 mm when the 2.25 mm stent is available.

          -  Target lesion greater than or equal to 28 mm in length by visual estimate.

        General</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Patient has other medical illness (e.g., cancer or congestive heart failure) or known
             history of substance abuse (alcohol, cocaine, heroin etc.) that may cause
             non-compliance with the clinical investigation plan, confound the data interpretation
             or is associated with a limited life expectancy (i.e., less than one year).

          -  Patient has a known hypersensitivity or contraindication to aspirin, either heparin or
             bivalirudin, both clopidogrel and ticlopidine, everolimus, cobalt, chromium, nickel,
             tungsten, acrylic and fluoro polymers or contrast sensitivity that cannot be
             adequately pre-medicated.

          -  Participation in another device or drug study or has completed the follow-up phase of
             another study within the last 30 days.

          -  Patient who is judged to have a lesion that prevents complete inflation of an
             angioplasty balloon.

          -  Patient has had a previous stent implant, either Bare Metal Stent (BMS) or Drug
             Eluting Stent (DES) within the target vessel(s)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>1600</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/07/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>The Northern Hospital - Epping</hospital>
    <hospital>Liverpool Hospital - New South Wales</hospital>
    <postcode>3076 - Epping</postcode>
    <postcode>2170 - New South Wales</postcode>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>St. Poelten</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Wels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Wien</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Charleroi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Roeselare</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Belo Horizonte</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Porto Alegre</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Hong Kong</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Beijing</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Guangzhou</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Shanghai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Copenhagen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Avignon Cedex 9</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bordeaux</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Brest Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Dijon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Massy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Montpellier</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>RENNES Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Rouen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bad Oeynhausen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bad Segeberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Coburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Dachau</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Dresden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hannover</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Ludwigshafen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mainz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Trier</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Villingen-Schwenningen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Athens</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Thessaloniki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Pécs</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Andhar Pradesh</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Andhra Pradesh</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Lucknow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>New Delhi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Holon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lecco</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Modena</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Palermo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Perugia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pisa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Reggio Emilia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Rome</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Rozzano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>San Donato</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Latvia</country>
      <state>Riga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Lembah Pantai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Breda</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Nieuwegein</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Bergen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Feiring</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Ustron</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warsaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Lisboa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Porto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Bloemfontein</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Pretoria</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Alicante</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Zaragoza</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Bern</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Geneve</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Lugano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Venezuela</country>
      <state>Caracas</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Abbott Vascular</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this Clinical Evaluation is the continued assessment of the XIENCE Everolimus
      Eluting Coronary Stent System (XIENCE V® and XIENCE PRIME EECSS) with the primary focus on
      clinical outcomes in the treatment of female patients with de novo coronary artery lesions,
      and the characterization of the female population undergoing stent implantation with a XIENCE
      stent.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00496938</trialwebsite>
    <publication>Morice MC. XIENCE V SPIRIT WOMEN clinical trial: characterization of the female population undergoing stent implantation. Womens Health (Lond). 2008 Sep;4(5):439-43. doi: 10.2217/17455057.4.5.439.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Marie-Claude Morice</name>
      <address>Institut Cardiovasculaire Paris Sud (ICPS), Paris, France</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>